CSL Bull Downbeat About Current Industry Growth of Immunoglobulin, Albumin -- Market Talk

Dow Jones04-13

2252 GMT - Jefferies pares its price target on pharmaceutical company CSL by 9.8% to A$212.00/share after assuming slower growth in immunoglobulin and albumin. Analyst David Stanton says investors' near-term focus is on CSL's performance in immunoglobulin in the U.S. and in albumin in China. Both markets appear underpenetrated, Jefferies says. So, the industry should grow over the medium term. "That said, industry feedback suggests that, at present, 2H industry growth rates in these markets are not stellar, throwing in question CSL's 'strong 2H ambition'," Jefferies says. Its EPS forecast for FY 2026 falls by around 2%, and for FY 2027 by some 5%. CSL ended last week at A$139.19. (david.winning@wsj.com; @dwinningWSJ)

(END) Dow Jones Newswires

April 12, 2026 18:52 ET (22:52 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2627016281?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-13 06:52","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2627016281","market":"nz","top_or_hot":-1,"title":"CSL Bull Downbeat About Current Industry Growth of Immunoglobulin, Albumin -- Market Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     2252 GMT - Jefferies pares its price target on pharmaceutical company CSL by 9.8% to A$212.00/share after assuming slower growth in immunoglobulin and albumin. Analyst David Stanton says investors' near-term focus is on CSL's performance in immunoglobulin in the U.S. and in albumin in China. Both markets appear underpenetrated, Jefferies says. So, the industry should grow over the medium term. \"That said, industry feedback suggests that, at present, 2H industry growth rates in these markets are not stellar, throwing in question CSL's 'strong 2H ambition',\" Jefferies says. Its EPS forecast for FY 2026 falls by around 2%, and for FY 2027 by some 5%. CSL ended last week at A$139.19. (david.winning@wsj.com; @dwinningWSJ) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  April 12, 2026 18:52 ET (22:52 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CSL Bull Downbeat About Current Industry Growth of Immunoglobulin, Albumin -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCSL Bull Downbeat About Current Industry Growth of Immunoglobulin, Albumin -- Market Talk\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-04-13 06:52</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     2252 GMT - Jefferies pares its price target on pharmaceutical company CSL by 9.8% to A$212.00/share after assuming slower growth in immunoglobulin and albumin. Analyst David Stanton says investors' near-term focus is on CSL's performance in immunoglobulin in the U.S. and in albumin in China. Both markets appear underpenetrated, Jefferies says. So, the industry should grow over the medium term. \"That said, industry feedback suggests that, at present, 2H industry growth rates in these markets are not stellar, throwing in question CSL's 'strong 2H ambition',\" Jefferies says. Its EPS forecast for FY 2026 falls by around 2%, and for FY 2027 by some 5%. CSL ended last week at A$139.19. (david.winning@wsj.com; @dwinningWSJ) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  April 12, 2026 18:52 ET (22:52 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK7067","symbol_name":"生物科技","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2627016281","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2627016281","pubTimestamp":1776034320,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"2252 GMT - Jefferies pares its price target on pharmaceutical company CSL by 9.8% to A$212.00/share after assuming slower growth in immunoglobulin and albumin. Analyst David Stanton says investors' near-term focus is on CSL's performance in immunoglobulin in the U.S. and in albumin in China. Both markets appear underpenetrated, Jefferies says. So, the industry should grow over the medium term. \"That said, industry feedback suggests that, at present, 2H industry growth rates in these markets are not stellar, throwing in question CSL's 'strong 2H ambition',\" Jefferies says. Its EPS forecast for FY 2026 falls by around 2%, and for FY 2027 by some 5%. CSL ended last week at A$139.19. ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK7067":"生物科技","CSL":"卡莱尔伙伴","CSL.AU":"CSL LIMITED","BK4086":"建筑产品","BK7508":"医药生物股","BK7511":"ESG概念","BK7501":"新冠治疗股","LU1169590202.USD":"ALLSPRING (LUX)  U.S. SELECT EQUITY \"I\" (USD) ACC","SG9999004303.SGD":"Nikko AM Shenton Global Opportunities SGD","LU0728928796.USD":"abrdn SICAV I - GLOBAL SMALL&MID-CAP SDG HORIZONS EQUITY \"A\" (USD) ACC","SGXZ23171101.USD":"NIKKO AM SHENTON GLOBAL OPPORTUNITIES (USD) ACC","LU1169589451.USD":"ALLSPRING (LUX)  U.S. SELECT EQUITY \"A\" (USD) ACC"},"translate_title":"CSL牛市对当前免疫球蛋白、白蛋白行业增长持悲观态度——市场讨论","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CSL":1.5,"CSL.AU":0.9},"content_text":"2252 GMT - Jefferies pares its price target on pharmaceutical company CSL by 9.8% to A$212.00/share after assuming slower growth in immunoglobulin and albumin. Analyst David Stanton says investors' near-term focus is on CSL's performance in immunoglobulin in the U.S. and in albumin in China. Both markets appear underpenetrated, Jefferies says. So, the industry should grow over the medium term. \"That said, industry feedback suggests that, at present, 2H industry growth rates in these markets are not stellar, throwing in question CSL's 'strong 2H ambition',\" Jefferies says. Its EPS forecast for FY 2026 falls by around 2%, and for FY 2027 by some 5%. CSL ended last week at A$139.19. (david.winning@wsj.com; @dwinningWSJ) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 12, 2026 18:52 ET (22:52 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2627016281","isCrawlerRequest":true}